PTCT as reported
PTC Therapeutics, Inc. reported $1.01B of revenue over the trailing twelve months, −43% on the year before. 11 reported series are charted on this page, each one as filed.
$1.01B
Revenue, trailing twelve months · to Q2 2026 · −43% against the twelve months before
- Net Income
- −$38M
Net Income · −106% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$40M
Free Cash Flow · −106% year on year · trailing twelve months to Q2 2026
- Op Margin
- 4.0%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.01B | −43% | Q2 2026 |
| Net Income | −$38M | −106% | Q2 2026 |
| EPS | −$0.58 | −108% | Q2 2026 |
| Gross Margin | 96% | n/a | Q4 2019 · 26 quarters behind |
| Op Margin | 4.0% | n/a | Q2 2026 |
| Net Margin | −13% | n/a | Q2 2026 |
| ROE | −172% | n/a | Q2 2026 |
| ROA | 11% | n/a | Q2 2026 |
| ROIC | −20% | n/a | Q2 2026 |
| Free Cash Flow | −$40M | −106% | Q2 2026 |
| P/E | 7.95 | n/a | Q4 2025 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
PTC Therapeutics, Inc. (PTCT) - Revenue & ProfitRevenue & ProfitPTC Therapeutics, Inc. (PTCT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com